Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study Meeting Abstract

  

Authors:	Burris, H. A.; Siu, L. L.; Infante, J. R.; Wheler, J. J.; Kurkjian, C.; Opalinska, J.; Smith, D. A.; Antal, J. M.; Gauvin, J. L.; Gonzalez, T.; Adams, L. M.; Bedard, P.; Gerecitano, J. F.; Kurzrock, R.; Moore, K. N.; Morris, S. R.; Aghajanian, C.
Abstract Title:	Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study
Meeting Title:	47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	29
Issue:	15 Suppl.
Meeting Dates:	2011 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2011-05-20
Language:	English
ACCESSION:	WOS:000208880301433
PROVIDER:	wos
DOI:	10.1200/jco.2011.29.15_suppl.3003
Notes:	Meeting Abstract: 3003 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/141394